Drug intelligence / Profile preview

dantrolene low-volume formulation

Development stage: Preclinical
Lead developer: Eagle Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

EP-4104 is a low-volume formulation of **dantrolene sodium** being developed for the treatment of COVID-19 infections and exertional heat stroke. Dantrolene is a muscle relaxant that works by inhibiting calcium release from the sarcoplasmic reticulum in skeletal muscle cells. This reduces muscle contraction and helps in managing conditions involving excessive muscle activity. The low-volume formulation enables easier intravenous administration, which is particularly valuable in acute or emergency settings[1][15].

Other names: EP 4104EP4104EP-4104dantrolene low-volume formulation

Targets

RYR2 (Ryanodine receptor 2)RYR3 (Ryanodine receptor 3)

Beyond the preview

Go deeper on dantrolene low-volume formulation.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dantrolene low-volume formulation.

Explore the full profile